Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Journal of Clinical Oncology ; (24): 904-907, 2014.
Article Dans Chinois | WPRIM | ID: wpr-452195

Résumé

Objective:To investigate the mutations of the epidermal growth factor receptor (EGFR) gene and its clinical signifi-cance in non-small cell lung cancer (NSCLC). Methods:The EGFR gene mutations of exons 18 to 21 in NSCLC were detected by us-ing the ADx-ARMS? detection kit method. Results:The total mutation percentage in exons 18 to 21 of the EGFR gene was 45.8%(98/214) in NSCLC. These mutations predominantly occur in exons 19 and 21. EGFR gene mutation percentages were found in exons 18 (0.93%, 2/214), 19 (22.0%,47/214), 20 (2.3%, 5/214), and exon 21 (20.6%, 44/214) in the NSCLC. Two NSCLC cases were identified to have double EGFR gene mutations of exons 19 and 21. EGFR gene mutations were more frequently observed with adenocarcinoma histology (50.3%, 93/185) than with squamous cell carcinoma (17.2%, 5/29) (P=0.001). EGFR gene mutations occur more frequently in NSCLC cases in women than in men (P=0.002). EGFR gene mutations were significantly higher in NSCLC with lymphatic metastasis (66.7%) than in NSCLC without lymphatic metastasis (39.5%) (P0.05). Conclusion:NSCLC, especially lung adenocar-cinomas, has exhibits frequent EGFR gene mutations in China. EGFR gene mutations in exons 19 and 21, combined with the clinical pathological features of lung cancer, can serve as the molecular marker to evaluate the efficacy of EGFR TKI for NSCLC patients.

2.
Journal of Central South University(Medical Sciences) ; (12): 631-633, 2011.
Article Dans Chinois | WPRIM | ID: wpr-814541

Résumé

OBJECTIVE@#To explore the relation between methylation status of RAS association domain family 1A (RASSF1A) in patients with advanced epithelial ovarian cancer and the clinical efficacy of cisplatin based neoadjuvant therapy.@*METHODS@#Forty patients with advanced epithelial ovarian cancer were selected and the methylation status of RASSF1A was evaluated by methylation specific PCR (MSP). The clinical efficacy was compared between patients with different methylation statuses of RASSF1A.@*RESULTS@#The response rate of 15 patients with methylation status in the promoter region was 26.6% and that of 25 patients without methylation status was 48.0%, with significant difference (P<0.05).@*CONCLUSION@#The methylation status of RASSF1A can influence the clinical efficacy of neoadjuvant therapy in patients with advanced epithelial ovarian cancer.


Sujets)
Adulte , Sujet âgé , Femelle , Humains , Adulte d'âge moyen , Jeune adulte , Carcinomes , Traitement médicamenteux , Génétique , Cisplatine , Méthylation de l'ADN , Traitement néoadjuvant , Méthodes , Tumeurs de l'ovaire , Traitement médicamenteux , Génétique , Paclitaxel , Régions promotrices (génétique) , Protéines suppresseurs de tumeurs , Génétique
SÉLECTION CITATIONS
Détails de la recherche